

To sequence or not to sequence,
that is the question:
**Maximising the
outcomes of ALK
inhibitors**

13.00–14.00

Friday 13 April 2018

Room A, Palexpo

Geneva, Switzerland

Light refreshments will be served prior to the symposium

Chair's welcome

Dear Colleague,

On behalf of the faculty, I am pleased to invite you to the Pfizer Oncology satellite symposium **'To sequence or not to sequence, that is the question: Maximising the outcomes of ALK inhibitors'**. The symposium will be held on **Friday 13 April 2018** from **13.00–14.00**, during the European Lung Cancer Congress (ELCC) in Geneva, Switzerland.

The approval of crizotinib in 2012 rapidly transformed the clinical landscape and lives of patients with ALK+ NSCLC, establishing a new era of targeted-treatment. This has heralded the development of further ALK inhibitors in recent times, providing physicians and their patients with ever-increasing treatment choices.

This fortuitous situation nevertheless raises the question of how physicians select the right ALK inhibitors to meet the needs of their patients. At our symposium, an expert panel of lung oncologists will present the current clinical and translational data on the use of ALK inhibitors in NSCLC and discuss how this evidence can be used to select a treatment sequence that can maximise patient outcomes.

I look forward to welcoming you to Geneva and I hope you will join us for what promises to be a highly engaging symposium.

Best regards



Silvia Novello

University of Turin

Department of Clinical and Biological Sciences

Turin, Italy

Programme

- 13.00 Welcome and introduction**
Professor Silvia Novello, Chair (Italy)
- 13.05 To sequence or not? The evidence for and against**
Dr Enriqueta Felip (Spain)
- 13.20 How can we sequence: Considerations of the patient and tumour biology**
Dr Fabrice Barlesi (France)
- 13.35 The reality of implementing a TKI sequence in today's healthcare environment: A focus on Europe**
Professor Silvia Novello (Italy)
- 13.45 Expert panel discussion**
Chaired by Professor Silvia Novello (Italy)
- 14.00 Meeting close**



Merck KGaA, Darmstadt, Germany, and Pfizer co-promote XALKORI (crizotinib) in the United States, Argentina, Canada, Japan, China, Turkey, and five European Union countries (France, Germany, Italy, Spain, and the United Kingdom).

This meeting is organised and funded by Pfizer Oncology

© Pfizer Pharma GmbH. All rights reserved. February 2018. PP-XLK-EUR-0600